Jonathan Zalevsky discusses dose response in atopic dermatitis study with three dose arms. They aim to replicate Phase Ib efficacy and consider reaching Dupixent standards commercially viable. Focus on induction data for Phase II results release, aiming for durable responses.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay